Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS

Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Related Keywords

,Medicine Oncologic Sciences ,Moffitt Cancer Center ,Experimental Therapeutics Program ,University Of South Florida ,Malignant Hematology Department ,College Of Medicine ,Rami Komrokji ,Malignant Hematology ,Oncologic Sciences ,South Florida ,Onclive Tv ,Myeloproliferative Neoplasms ,Nct03682536 ,Myelodysplastic Syndromes ,